DK1420827T3 - 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter - Google Patents

5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter

Info

Publication number
DK1420827T3
DK1420827T3 DK02794796T DK02794796T DK1420827T3 DK 1420827 T3 DK1420827 T3 DK 1420827T3 DK 02794796 T DK02794796 T DK 02794796T DK 02794796 T DK02794796 T DK 02794796T DK 1420827 T3 DK1420827 T3 DK 1420827T3
Authority
DK
Denmark
Prior art keywords
parathyroid hormone
cnac
oral administration
administration agent
hormone fragments
Prior art date
Application number
DK02794796T
Other languages
English (en)
Inventor
Simon David Bateman
Moise Azria
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1420827T3 publication Critical patent/DK1420827T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK02794796T 2001-08-17 2002-08-16 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter DK1420827T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number Publication Date
DK1420827T3 true DK1420827T3 (da) 2009-12-21

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02794796T DK1420827T3 (da) 2001-08-17 2002-08-16 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter

Country Status (26)

Country Link
US (4) US20040242478A1 (da)
EP (1) EP1420827B8 (da)
JP (2) JP4959917B2 (da)
KR (1) KR20040030120A (da)
CN (1) CN1279981C (da)
AT (1) ATE443527T1 (da)
AU (1) AU2002333443C1 (da)
BR (1) BRPI0211932B1 (da)
CA (1) CA2453646C (da)
CO (1) CO5560586A2 (da)
CY (1) CY1109661T1 (da)
DE (1) DE60233803D1 (da)
DK (1) DK1420827T3 (da)
EC (1) ECSP044961A (da)
ES (1) ES2333587T3 (da)
HU (1) HUP0401441A3 (da)
IL (2) IL159714A0 (da)
MX (1) MXPA04001418A (da)
NO (1) NO328069B1 (da)
NZ (1) NZ531018A (da)
PL (1) PL210258B1 (da)
PT (1) PT1420827E (da)
RU (1) RU2322256C2 (da)
SI (1) SI1420827T1 (da)
WO (1) WO2003015822A1 (da)
ZA (1) ZA200400242B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ307145B6 (cs) * 2001-06-01 2018-02-07 Novartis Ag Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby
NZ531018A (en) * 2001-08-17 2006-03-31 Novartis Ag 5-CNAC as oral delivery agent for parathyroid hormone fragments
JP2006515829A (ja) * 2002-04-10 2006-06-08 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
CN1856321B (zh) 2003-07-23 2012-10-03 诺瓦提斯公司 降钙素在骨关节炎中的用途
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
WO2006135915A2 (en) * 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8026392B2 (en) 2005-09-19 2011-09-27 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
AU2007289344B2 (en) * 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
DE602008006700D1 (da) 2007-03-02 2011-06-16 Novartis Ag
JP5555634B2 (ja) 2007-11-02 2014-07-23 エミスフェア テクノロジーズ インコーポレイティッド ビタミンｂ１２欠乏症を治療するための方法
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
IL283258B2 (en) * 2015-02-09 2023-11-01 Entera Bio Ltd A preparation for the treatment of hypothyroidism
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
CA2124792C (en) * 1991-12-17 2000-07-04 Ann D. Geddes Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
KR100291620B1 (ko) * 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2319672C (en) * 1997-02-07 2011-01-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2003533167A (ja) * 1998-11-25 2003-11-11 ザ ゼネラル ホスピタル コーポレーション アミノ末端改変副甲状腺ホルモン（ｐｔｈ）アナログ
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
CA2402719C (en) * 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
CZ307145B6 (cs) 2001-06-01 2018-02-07 Novartis Ag Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby
NZ531018A (en) * 2001-08-17 2006-03-31 Novartis Ag 5-CNAC as oral delivery agent for parathyroid hormone fragments
DE602004023093D1 (de) * 2003-07-11 2009-10-22 Novartis Ag N mit einem abgabemittel in mikronisierter form

Also Published As

Publication number Publication date
AU2002333443C1 (en) 2009-10-08
CN1279981C (zh) 2006-10-18
IL159714A0 (en) 2004-06-20
NO20040598L (no) 2004-02-10
CN1543357A (zh) 2004-11-03
MXPA04001418A (es) 2004-05-27
KR20040030120A (ko) 2004-04-08
CO5560586A2 (es) 2005-09-30
BR0211932A (pt) 2004-10-26
ECSP044961A (es) 2004-03-23
WO2003015822A1 (en) 2003-02-27
AU2002333443B2 (en) 2006-06-29
CA2453646A1 (en) 2003-02-27
ES2333587T3 (es) 2010-02-24
US20120088725A1 (en) 2012-04-12
IL159714A (en) 2010-12-30
BRPI0211932B1 (pt) 2016-12-06
RU2004107899A (ru) 2005-05-10
PL365388A1 (en) 2005-01-10
JP2005501852A (ja) 2005-01-20
PT1420827E (pt) 2009-12-15
JP2009242410A (ja) 2009-10-22
CY1109661T1 (el) 2014-08-13
PL210258B1 (pl) 2011-12-30
RU2322256C2 (ru) 2008-04-20
US20090264367A1 (en) 2009-10-22
JP4959917B2 (ja) 2012-06-27
ZA200400242B (en) 2004-11-18
US20040242478A1 (en) 2004-12-02
SI1420827T1 (sl) 2010-01-29
ATE443527T1 (de) 2009-10-15
EP1420827B8 (en) 2009-12-23
EP1420827B1 (en) 2009-09-23
CA2453646C (en) 2008-09-30
NZ531018A (en) 2006-03-31
HUP0401441A3 (en) 2012-09-28
DE60233803D1 (de) 2009-11-05
HUP0401441A2 (hu) 2004-12-28
NO328069B1 (no) 2009-11-23
US9272040B2 (en) 2016-03-01
US20060217313A1 (en) 2006-09-28
EP1420827A1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
DK1420827T3 (da) 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
AU2003301190A8 (en) Administration of capsaicinoids
IL220043A0 (en) Methods for producing ??-galactosidase a compositions
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
LU91281I2 (fr) Preotact-hormone parathyroïde
GT199700009AA (es) Terapia combinada para la osteoporosis
DE60218842D1 (de) Orale verabreichung von parathyroidhormon und calcitonin
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL368686A1 (en) Novel aminobenzoephenones
PL370361A1 (en) Alkyl urea retinoid agonists i
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
AU2003286617A8 (en) Calcitonin drug-oligomer conjugates, and uses thereof
PL370459A1 (en) Substituted urea retinoid agonists ii
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture